# Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

> **NCT03050411** · PHASE1 · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Apatinib Mesylate Tablets
- **DRUG:** EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)

## Key facts

- **NCT ID:** NCT03050411
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2019-06
- **Final completion:** 2019-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050411, "Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03050411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*